• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     Norwegian Knowledge Centre for the Health Services (NOKC) [End-of-life care - how to find the appropriate level and intensity of medical treatment of seriously ill and dying patients]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (melanoma) - Addendum to Commission A18-61]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/tenofovir alafenamide (HIV) - Addendum to Commission A16-30]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a SGB V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/metformin - Addendum to Commission A16-13]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin: benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Empagliflozin and dapagliflozin for the treatment of type 2 diabetes mellitus]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Addendum to Commission A21-93]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin - Addendum to Commission A16-12]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Addendum to Commission A18-20]
2013     The Swedish Council on Health Technology Assessment (SBU) [Emergency care for the elderly patients who are in the poorest health]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Embolization or sclerotherapy of pelvic veins in pelvic congestion syndrome]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Embolization of uterine fibroids - Early Warning on New Health Technology]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Embolization in the treatment of uterine myoma]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: addendum to commission A15-61]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) - Benefit assessment according to §35a Social Code Book (SGB) V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Addendum to Commission A19-80]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab (multiple myeloma) - Addendum to Commission A16-32]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elotuzumab - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa (mucopolysaccharidosis type IVA) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (new scientific findings)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eliglustat - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Elexacaftor/tezacaftor/ivacaftor in cystic fibrosis]
2014     Haute Autorite de sante (HAS) [Elements to evaluate for managing a patient in outpatient surgery]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrosurgical units in surgery]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Electronic patient record at an osteoporotic outpatient department - a Health Technology Assessment]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Electronic patient record at an osteoporotic outpatient department - a health technology assessment]
2011     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Electronic Clinical Guides: breast cancer]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic Navigation Bronchoscopy: Use in Dying for Lung Nodules Resection. Horizon Scanning Technologies]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Electrical stimulation devices to treat delayed unions and pseudarthrosis]
2012     Haute Autorite de sante (HAS) [Elbow joint implants]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elbasvir/grazoprevir (chronic hepatitis C): Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elbasvir/grazoprevir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eladocagene Exuparvovec (aromatic L-amino acid decarboxylase deficiency, = 18 months) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elacestrant (breast cancer; = 1 prior therapy) – Benefit assessment according to §35a Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [ELA2 gene point mutation analysis]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eftrenonacog alfa (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eftrenonacog alfa - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efmoroctocog alfa - Benefit assessment according to § 35a Social Code Book V]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [eFlow® vibrating membrane nebulizer for the treatment of cystic fibrosis]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efgartigimod alfa (myasthenia gravis) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficiency, effectiveness and safety of mechanical ventricular assistance with HeartWare® device in terminal heart failure]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficiency, effectiveness and safety of mechanical ventricular assistance with HeartWare® device in terminal heart failure]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Efficiency of the induction of personalised psychiatric rehabilitation through assessment of, and continuous feedback on, needs and outcomes - a catchment area observational trial]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficiency of the "housing first" approach for people who are homeless and living with mental illness or with disorders associated to psychoactive substances]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficiency of short-term social and psychological therapies: Systematic review]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Efficiency of physiotherapeutic care in Parkinson's disease]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficiency of peritoneal dialysis versus hemodialysis for the treatment of renal insufficiency]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficiency of 3D reconstruction in maxillofacial surgery]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Efficiency in the use of operating surgical blocks. Definition of indicators]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Efficacy, safety, and usefulness of genistein in patients with Sanfilippo syndrome]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, safety of high intensity focused ultrasound (HIFU-ExAblate)]
2004     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, safety and indications of hybrid PET-CT system]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of transcutaneous nerve stimulation for the treatment of chronic musculoskeletal pain]
2014     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of platelet rich plasma in the treatment of aseptic nonunion]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of electrical spinal cord stimulation for the treatment of chronic musculoskeletal pain]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, safety and efficiency of computed tomographic colonography vs. colonoscopy as colorectal cancer screening test]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, safety and economic assessment of the percutaneous aortic valve implantation]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, safety and economic assessment of the percutaneous aortic valve implantation]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, effectivity and efficiency of liquid cytology for cervical cancer screening and HPV infection diagnosis]
2017     Andalusian Health Technology Assessment Area (AETSA) [Efficacy, effectiveness and safety of physiotherapy in patients with multiple sclerosis. Rapid response]
2004     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, effectiveness and safety of photodynamic therapy. Economical impact in the Community of Madrid]
2004     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, effectiveness and safety of photodynamic therapy in age-related macular degeneration and pathologic myopia. Economic impact in the Community of Madrid]
2012     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, effectiveness and safety of behavioural interventions in patients with autism spectrum disorders]
2010     Andalusian Health Technology Assessment Area (AETSA) [Efficacy of oral/buccal insulin in the treatment of diabetes mellitus]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficacy of neglect interventions for Indigenous children, families and communities]
2008     Andalusian Health Technology Assessment Area (AETSA) [Efficacy of laparoscopy in hepatobiliary pathology]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficacy of intraoperative radiation therapy]
2021     Basque Office for Health Technology Assessment (OSTEBA) [Efficacy of high flow oxygen therapy for the treatment of respiratory distress in children]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Efficacy of early intensive behavioral intervention in autism spectrum disorders]
2005     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy of colorectal cancer (CRC) screening in asymptomatic first degree relatives of patients with CRC or adenomas. Genetic tests]
2008     Andalusian Health Technology Assessment Area (AETSA) [Efficacy of biventricular pacemakers for heart failure]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy of 123i-ioflupane (DaTSCAN) on the diagnosis of parkinsonism syndromes. Systematic review and case registry]
2021     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Efficacy and safety of yoga on selected clinical conditions]
2013     Andalusian Health Technology Assessment Area (AETSA) [Efficacy and safety of ventricular assist devices]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Efficacy and safety of transanal irrigation in adults with bowel dysfunction]
2012     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Efficacy and safety of tocilizumab in treating rheumatoid arthritis]